Antiviral Activity of Chitosan Nanoparticles Encapsulating Curcumin Against Hepatitis C Virus Genotype 4a in Human Hepatoma Cell Lines [Corrigendum]

Loutfy SA, Elberry MH, Farroh KY, et al. *Int J Nanomedicine*. 2020;15:2699–2715.

The authors apologize for this error and advise it does not affect the results of the paper

The authors have advised Figure 8 on page 2712 is incorrect. The correct Figure 8 is shown below.

Figure 8 (A) The scanned densitometry Western blot of viral replication in Huh7 (a) versus β -actin (b); lane 1, protein levels of infected untreated cells; lane 2, infected cells treated with curcumin; lane 3, infected cells treated with CsNPs; lane 4, infected cells treated with curcumin chitosan nanocomposite. **(B)** The scanned densitometry western blot of viral entry (a) versus β -actin (b) protein levels in positive; lane 1, untreated infected cells; lane 2, cells treated with curcumin; lane 3, cells treated with CsNPs; lane 4, cells treated with curcumin chitosan nanocomposite; lane 5, cells treated with sofosbuvir. HCV core protein at size of 22 KD.